1-10 of 10
Pingping Mao
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Cell Line–Specific Network Models of ER+ Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations

Free
Jorge Gómez Tejeda Zañudo, Pingping Mao, Clara Alcon, Kailey Kowalski, Gabriela N. Johnson, Guotai Xu, Jose Baselga, Maurizio Scaltriti, Anthony Letai, Joan Montero, Réka Albert, Nikhil Wagle
Journal: Cancer Research
Cancer Res (2021) 81 (17): 4603–4617.
https://doi.org/10.1158/0008-5472.CAN-21-1208
Published: 01 September 2021
View articletitled, Cell Line–Specific Network Models of ER+ Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations
Open the PDF for Cell Line–Specific Network Models of ER+ Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations in another window
Includes: Supplementary data
Journal Articles

Abstract PS5-10: Esr1 mutation as a potential predictor of abemaciclib benefit following prior cdk4/6 inhibitor (cdk4/6i) progression in hormone receptor-positive (hr+) metastatic breast cancer (mbc): A translational investigation

Free
Seth A. Wander, Hyo S. Han, Gabriela N. Johnson, Maxwell R. Lloyd, Pingping Mao, Utthara Nayar, Kailey Kowalski, Casey R. Stein, Veronica Mariotti, Leslie SL Kim, Maren Levin, Jing Xi, Apurva Pandey, Siobhan Dunne, Azadeh Nasrazadani, Adam Brufsky, Kevin Kalinsky, Cynthia X Ma, Joyce O’Shaughnessy, Nikhil Wagle, Aditya Bardia
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PS5-10.
https://doi.org/10.1158/1538-7445.SABCS20-PS5-10
Published: 15 February 2021
View articletitled, Abstract PS5-10: Esr1 mutation as a potential predictor of abemaciclib benefit following prior cdk4/6 inhibitor (cdk4/6i) progression in hormone receptor-positive (hr+) metastatic breast cancer (mbc): A translational investigation
Journal Articles

Abstract PD7-08: Igf1r mediates cdk4/6 inhibitor (cdk4/6i) resistance in tumor samples and in cellular models

Free
Seth A. Wander, Pingping Mao, Maxwell R. Lloyd, Gabriela N. Johnson, Kailey Kowalski, Utthara Nayar, Lillian M. Guenther, Kimberly Stegmaier, Eric P. Winer, Nancy U. Lin, Nikhil Wagle
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): PD7-08.
https://doi.org/10.1158/1538-7445.SABCS20-PD7-08
Published: 15 February 2021
View articletitled, Abstract PD7-08: Igf1r mediates cdk4/6 inhibitor (cdk4/6i) resistance in tumor samples and in cellular models
Journal Articles

Abstract PD2-09: The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC)

Free
Seth A. Wander, Ofir Cohen, Xueqian Gong, Gabriela N. Johnson, Jorge Buendia-Buendia, Maxwell Lloyd, Dewey Kim, Flora Luo, Pingping Mao, Karla Helvie, Kailey Kowalski, Utthara Nayar, Stephen Parsons, Ricardo Martinez, Lacey Litchfield, Xiang Ye, Chun Ping Yu, Valerie Jansen, Levi A. Garraway, Eric P. Winer, Sara M. Tolaney, Nancy U. Lin, Sean Buchanan, Nikhil Wagle
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): PD2-09.
https://doi.org/10.1158/1538-7445.SABCS19-PD2-09
Published: 15 February 2020
View articletitled, Abstract PD2-09: The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC)
Journal Articles

Abstract P6-10-08: AKT1 alterations following exposure to endocrine-based therapy in patients with hormone-receptor positive (HR+) metastatic breast cancer (MBC): Clinical and functional implications

Free
Seth Wander, Pingping Mao, Maxwell Lloyd, Kailey Kowalski, Gabriela N. Johnson, Giuliana Malvarosa, Beverly Moy, Leif W. Ellisen, John Iafrate, Nikhil Wagle, Aditya Bardia
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P6-10-08.
https://doi.org/10.1158/1538-7445.SABCS19-P6-10-08
Published: 15 February 2020
View articletitled, Abstract P6-10-08: AKT1 alterations following exposure to endocrine-based therapy in patients with hormone-receptor positive (HR+) metastatic breast cancer (MBC): Clinical and functional implications
Journal Articles

Abstract GS2-02: Acquired activating mutations in RTKs confer endocrine resistance in ER+ metastatic breast cancer through ER-reprogramming, MAPK signaling, and an induced stem-like cell state

Free
Ofir Cohen, Pingping Mao, Utthara Nayar, Jorge E Buendia-Bue, Dewey Kim, Esha Jain, Karla Helvie, Daniel Abravanel, Kailey J Kowalski, Christian Kapstad, Samuel Freeman, Victor Adalsteinsson, Seth A Wander, Adrienne G Waks, Gad Getz, Aviv Regev, Eric Winer P Winer, Nancy U Nancy U. Lin, Nikhil Wagle
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): GS2-02.
https://doi.org/10.1158/1538-7445.SABCS19-GS2-02
Published: 15 February 2020
View articletitled, Abstract GS2-02: Acquired activating mutations in RTKs confer endocrine resistance in ER+ metastatic breast cancer through ER-reprogramming, MAPK signaling, and an induced stem-like cell state
Journal Articles

Abstract 314: Acquired FGF and FGFR alterations confer resistance to estrogen receptor (ER) targeted therapy in metastatic ER+ breast cancer

Free
Pingping Mao, Ofir Cohen, Kailey Kowalski, Justin Kusiel, Jorge Buendia, Pedro Exman, Seth A. Wander, Adrienne G. Waks, Eric P. Winer, Nancy U. Lin, Nikhil Wagle
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 314.
https://doi.org/10.1158/1538-7445.AM2019-314
Published: 01 July 2019
View articletitled, Abstract 314: Acquired FGF and FGFR alterations confer resistance to estrogen receptor (ER) targeted therapy in metastatic ER+ breast cancer
Journal Articles

Abstract 675: Network modeling of drug resistance mechanisms and drug combinations in breast cancer

Free
Jorge Gómez Tejeda Zañudo, Pingping Mao, Joan Montero, Guotai Xu, Kailey J. Kowalski, Gabriela N. Johnson, José Baselga, Maurizio Scaltriti, Anthony G. Letai, Nikhil Wagle, Reka Albert
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 675.
https://doi.org/10.1158/1538-7445.AM2019-675
Published: 01 July 2019
View articletitled, Abstract 675: Network modeling of drug resistance mechanisms and drug combinations in breast cancer
Journal Articles

Abstract 4605: STK17A is a potential therapeutic target in glioblastoma

Free
Pingping Mao, Mary P. Jardine, Gilbert J. Rahme, Eric C. Yang, Janice Tam, Anita Kodali, Bijesh Biswal, Camilo E. Fadul, Arti B. Gaur, Mark A. Israel, Alexandre Pletnev, Michael Spinella
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 4605.
https://doi.org/10.1158/1538-7445.AM2014-4605
Published: 01 October 2014
View articletitled, Abstract 4605: STK17A is a potential therapeutic target in glioblastoma
Journal Articles

Abstract 2958: The novel protein kinase STK17A is a direct p53 target gene that mediates response to genotoxic and nutritional stress in a cancer cell context-dependent manner

Free
Pingping Mao, Mary Jardine, Lynn Niemaszyk, Jessica Haghkerdar, Eric Yang, Esty G. yanco, Damayanti Desai, Maroun Beyrouthy, Joanna S. Kerley-Hamilton, Sarah J. Freemantle, Michael J. Spinella
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 2958.
https://doi.org/10.1158/1538-7445.AM2012-2958
Published: 15 April 2012
View articletitled, Abstract 2958: The novel protein kinase STK17A is a direct p53 target gene that mediates response to genotoxic and nutritional stress in a cancer cell context-dependent manner